Table 3 Baseline characteristics of patients post-CA grouped according to TyG index tertile

Demographic data

Age (years)

65(56–76)

65(56–74)

62(53–69)

<0.001

Male (n (%))

232(68.2)

205(60.1)

211(62.1)

0.072

BMI

27.3(23.7–31.9)

28.6(24.9–32.9)

31.0(26.6–36.3)

<0.001

Vital signs

HR (/min)

78(63–91)

78(64–93)

81(68–96)

0.012

SBP (mmHg)

116(101–135)

114(99–134)

114(100–137)

0.928

DBP (mmHg)

65(56–75)

63(54–73)

65(55–77)

0.219

Temperature (℃)

36.6(35.7–37.1)

36.5(34.5–37.0)

36.5(34.3–37.3)

0.226

SpO2 (%)

99(95–100)

99(96–100)

99(95–100)

0.079

Comorbidities

MI (n (%))

90(26.5)

88(25.8)

71(20.9)

0.179

AF (n (%))

34(10.0)

35(10.3)

33(9.7)

0.971

CHF (n (%))

42(12.4)

30(8.8)

36(10.6)

0.321

CKD (n (%))

18(5.3)

21(6.2)

19(5.6)

0.885

ARF (n (%))

61(17.9)

70(20.5)

102(30.0)

<0.001

Diabetes (n (%))

33(9.7)

45(13.2)

48(14.1)

0.182

Hypertension (n (%))

43(12.6)

49(14.4)

41(12.1)

0.648

Cardiogenic shock (n (%))

35(10.3)

35(10.3)

52(15.3)

0.066

Non-shockable rhythm

(n (%))

98(28.8)

79(23.2)

78(22.9)

0.133

Clinical indices

RBC (M/mcl)

4.0(3.5–4.5)

4.0(3.4–4.5)

4.2(3.6–4.7)

0.002

WBC (K/mcl)

11.7(9.0-16.3)

13.0(10.0-18.5)

15.6(10.8–21.9)

<0.001

Platelet (K/mcl)

186(140–242)

203(155–254)

203(151–250)

0.020

HB (g/dL)

11.9(10.0-13.4)

11.8(10.0-13.5)

12.6(10.3–14.2)

0.002

Creatinine (mg/dL)

1.10(0.84–1.80)

1.20(0.86–2.05)

1.49(0.99–2.25)

0.066

BUN (mg/dL)

20.0(14.0–32.0)

21.0(15.0–32.0)

24.0(17.0–37.0)

0.203

FBG (mg/dL)

135.0(116.2-163.8)

162.3(136.6-200.8)

220.7(171.4-278.9)

<0.001

Triglyceride (mg/dL)

70.0(56.0–87.0)

118.0(95.5-139.3)

197.0(152.0-261.3)

<0.001

Tyg-index

8.51(8.24–8.72)

9.20(9.04–9.32)

9.91(9.70–10.30)

<0.001

TC (mg/dL)

126.3(98.4-158.9)

136.0(110.1-164.3)

144.0(113.0-176.2)

<0.001

HDL (mg/dL)

41.5(32.0–52.0)

38.0(30.0-46.8)

32.0(25.3–43.0)

<0.001

LDL (mg/dL)

66.0(44.1–93.8)

71.4(49.8–96.0)

78.0(49.3–99.0)

0.027

Arterial pH

7.35(7.28–7.41)

7.36(7.29–7.43)

7.31(7.23–7.40)

0.002

PaCO2 (mmHg)

41(33–47)

38(33–46)

40(33–46)

0.026

APS

71(38–101)

76(47–103)

94(62–120)

<0.001

APACHE IV

85(51–114)

89(60–117)

104(72–129)

<0.001

Treatment measures

Bystander CPR (n (%))

134(39.4)

117(34.3)

113(33.2)

0.199

CPR>15 min (n (%))

CPR<15 min (n (%))

26(7.6)

108(31.8)

26(7.6)

92(27.0)

37(10.9)

78(22.9)

0.223

0.035

Unwitnessed status (n (%))

13(38.2)

8(2.3)

13(3.8)

0.463

Enteral nutrition (n (%))

2(0.6)

3(0.9)

0(0)

0.246

Amiodarone (n (%))

10(2.9)

5(14.7)

12(3.5)

0.224

Dobutamine (n (%))

7(2.1)

7(2.1)

5(1.5)

0.808

Dopamine (n (%))

39(11.5)

39(11.4)

32(9.4)

0.611

Epinephrine (n (%))

18(5.3)

18(5.3)

20(5.9)

0.925

Statin (n (%))

3(0.9)

8(2.3)

4(1.2)

0.244